Skip to main content
Dana-Farber
  • person
  • dana-farber.org
  • Search
  • Featured Specialties
    • Breast Oncology
    • Gastrointestinal Oncology
    • Genitourinary Oncology
    • Gynecologic Oncology
    • Hematologic Oncology
    • Pediatric Oncology
  • Find a Physician
  • Find a Clinical Trial
  • Refer a Patient
  • Contact Us

Antonio Giordano, MD Giordano, PhD

Assistant Professor of Medicine, Harvard Medical School

Antonio Giordano, MD Giordano, PhD

Dr. Giordano completed his medical school and oncology fellowship at University of Naples Federico II in Italy in 2004 and 2009, respectively. The passion for research was the motivation behind his pursuit of starting a PhD Program in medical oncology and immunology at the Second University of Naples and participating in the exchange program with The University of Texas MD Anderson Cancer Center. During the four years spent as faculty at MD Anderson, he consolidated his solid foundation in breast clinical oncology, transitional and basic science research, and has made tremendous contributions to the field of breast cancer biology and circulating biomarkers. He subsequently worked as faculty at MUSC in Charleston SC from 2016 to 2020. In 2020, Dr. Giordano joined the staff of Brigham and Women's Hospital and Dana-Farber Cancer Institute, where he is a medical oncologist and clinical investigator in the Breast Oncology Center.

View full profile


Related Videos

Antonio Giordano, MD, PhD Discusses Novel CDK4-Selective Inhibitor Video

Antonio Giordano, MD, PhD Discusses Novel CDK4-Selective Inhibitor

Dana-Farber's Antonia Giordano, MD, PhD shares new data on a novel CDK4-selective inhibitor in como with letrozole as 1st line treatment in HR+/HER2 Metastatic Breast Cancer.

Research Update for Triple Negative MBC | 2021-2022 EMBRACE MBC Virtual Forum Series Video

Research Update for Triple Negative MBC | 2021-2022 EMBRACE MBC Virtual Forum Series

Antonio Giordano, MD, PhD; Sarah Sammons, MD; and Morgan Rutter, MS, BSN, RN, discuss advances in research and treatment for patients with triple negative metastatic breast cancer.

Connect with us

Facebook_DanaFarber_Blue_icon X_DanaFarber_Blue_icon Instagram_DanaFarber_Blue_icon Youtube_DanaFarber_Blue_icon LinkedIn_DanaFarber_Blue_icon
  • About Us
  • Research
  • Medical Oncology Spotlight
  • Find a Clinical Trial
  • Find a Physician
  • Refer a Patient
  • Clinical Resources
  • Dana-Farber
Powered by BroadcastMedBROADCASTMED